THE MITOSYNE METHOD

Evidence is useful only when its context survives.

A result changes meaning when the form, dose, population, duration, comparator or endpoint changes. The MitoSyne method keeps those details attached from first review to final disclosure.

This page explains the current MitoSyne review method. It is not a product claim or a substitute for personal medical advice.

Layered research documents with an abstract evidence record and copper audit path.
MitoSyne Review Method v1.0 Last reviewed: 28 July 2026

What this method is designed to do.

Keep the identity, exposure, population, comparison, outcomes and limitations attached to a conclusion from first review to final publication.

What it does not do.

It does not turn every study into a claim, assign certainty that the record cannot support or replace personal medical judgment.

HOW WE READ

Five questions behind every conclusion.

  1. 01

    What was studied?

    A familiar ingredient name can hide materially different compounds, extracts, salts, ratios or delivery forms. The first task is to identify the exact material used in the research and determine whether it matches the material being considered. When identity is unclear, the conclusion remains unclear.

  2. 02

    Who took part?

    Results belong first to the people who were actually studied. Age, health status, baseline nutrient status, medication use, training status and other inclusion criteria can change what a finding means. A conclusion should not quietly expand beyond the population that produced it.

  3. 03

    At what amount and schedule?

    Dose, timing, frequency and duration are part of the intervention—not minor details. Evidence at one amount does not automatically support a different amount, and a short study cannot establish what happens over years. The studied exposure should remain visible.

  4. 04

    What was the comparison?

    A result depends on what the intervention was compared with: placebo, usual care, another ingredient, a different dose or no intervention. That comparison determines what the difference actually means.

  5. 05

    What changed—and what did not?

    A statistically significant result may still be small, indirect or limited to one outcome among many. A useful review should show the measured result, its practical scale, adverse events, null findings and important uncertainty.

EVIDENCE TYPES

Different evidence answers different questions.

Systematic reviews and meta-analyses

Useful for seeing patterns across multiple studies and estimating consistency. Their conclusions remain limited by the quality, comparability and publication bias of the included evidence. A pooled number does not erase differences in form, dose or population.

Human intervention studies

Useful for testing whether a defined intervention changes a measured outcome under specific conditions. Randomization and controls can strengthen causal inference, but duration, adherence, sample size and endpoint choice still determine how broadly the result can be used.

Observational evidence

Useful for identifying associations, long-term patterns and questions that may be difficult to study experimentally. It cannot by itself prove that an exposure caused an outcome, because confounding, measurement error and reverse causation may remain.

Mechanistic and preclinical evidence

Useful for understanding plausibility, pathways and questions worth testing. Cell, animal and biochemical findings do not establish a human benefit on their own. They inform the map; they are not the destination.

REVIEW FILTERS

What does not survive review.

  1. 01

    Identity mismatch

    Research on one material should not be presented as proof for a materially different form.

  2. 02

    Dose mismatch

    A conclusion should not be stretched from a studied exposure to an unsupported amount or schedule.

  3. 03

    Population leap

    Findings should not be generalized beyond the people studied without a clear reason and qualification.

  4. 04

    Surrogate overreach

    A change in an intermediate marker should not be treated as proof of a meaningful health outcome.

  5. 05

    Selective endpoints

    A favorable result should not be isolated from null findings, adverse events or the wider outcome set.

  6. 06

    Single-study certainty

    One study can inform a question; it rarely closes it.

  7. 07

    Unexamined conflicts

    Funding, author interests and analytical choices should remain visible where they may affect interpretation.

  8. 08

    Unverifiable sourcing

    A claim should not rely on a citation, ingredient identity or document that cannot be checked.

VISIBLE CONTEXT

A conclusion should leave an audit trail.

Each evidence record keeps the source, material, exposure, population, methods, outcomes and limitations in one view. The goal is not to make every visitor read like a reviewer. It is to make the path behind a statement inspectable.

Diagram linking source, material, exposure, population, outcomes and limitations.
Source

Citation, publication type and permanent identifier.

Material and form

The exact compound, extract, ratio, salt, isomer or delivery form.

Dose and schedule

Amount, frequency, timing and relevant co-interventions.

Population

Sample size, age, health status and important inclusion criteria.

Duration

Intervention length and follow-up period.

Comparator

Placebo, usual care, no intervention, alternative product or dose.

Endpoints

Primary and secondary outcomes, including null results.

Effect and uncertainty

Magnitude, confidence interval and practical context where available.

Adverse events

Reported harms, tolerability and discontinuations.

Funding and conflicts

Declared support, author interests and material affiliations.

Reviewer notes

Important design limitations and unresolved questions.

Approved use

The countries and parts of the site where the conclusion may appear.

PLAIN-LANGUAGE GLOSSARY

Terms that should never be left unexplained.

Comparator

What the intervention was compared with, such as placebo, usual care, another dose or no intervention.

Endpoint

The outcome the study was designed to measure.

Surrogate outcome

An intermediate marker used in place of a direct health outcome. It may be informative without proving that the health outcome changed.

Confidence interval

A range showing the uncertainty around an estimate. Wider ranges usually mean less precision.

Effect size

The size of the observed difference, not merely whether a statistical threshold was crossed.

Risk of bias

Features of a study that may systematically distort the result.

Confounding

A factor linked to both the exposure and the outcome that may create or obscure an association.

Indirectness

A mismatch between the evidence and the exact population, material, comparison or outcome relevant to the decision.

Publication bias

The possibility that studies with favorable or statistically significant findings are more likely to be published.

Generalizability

How reasonably a finding may apply beyond the people and conditions that were actually studied.